Pittsburgh is at a familiar crossroads, with use of a dangerous drug surging and government slow to take action. Xylazine, the large-mammal tranquilizer, hasn’t yet saturated the illicit drug market. Making xylazine test strips widely and inexpensively available will save lives and help governments track the drug’s movement. Once people become widely dependent on xylazine, it will already be too late.

A decade ago, the same story played out with fentanyl — and the regional and national response came too slowly. Test strips were only legalized in Pennsylvania a year ago, long after the drug had established itself as the main driver of overdoses and deaths. Former Mayor Bill Peduto had permitted them in Pittsburgh in a 2021 executive order.

Test strips don’t just save users’ lives. They let city and state officials track the spread of the drug, providing crucial information. While Pennsylvania leads the nation in xylazine-related overdose deaths, that surge began in Philadelphia, not Pittsburgh. It hasn’t yet taken over here, making tracking and data collection all the more vital.

Xylazine, known as “tranq” or as “tranq dope” when mixed with fentanyl, causes respiratory depression, low blood pressure and unconsciousness. The most striking effect of the drug is the necrotic wounds it causes, which can appear anywhere on the body. Doctors theorize that the drug in the bloodstream might collapse blood vessels, causing tissue to die from lack of oxygen.

Advertise with us

As a non-opioid, xylazine doesn’t respond to overdose reversal drugs like naloxone. Medications that can help with opioid use disorder, like methadone, can’t be used against xylazine.

But there’s still reason to hope. Xylazine appears to be less deadly than fentanyl, or at least only deadly in combination with other drugs. The gruesome open wounds can lead to serious infections, but are treatable, and improve when an affected person stops taking xylazine.

Xylazine withdrawal, however, is brutal, causing dizziness, numbness, nausea and extreme anxiety. The fear of withdrawal is often worse than the horror of the necrotic wounds.

That’s why it’s important to act now, before xylazine is fully established in Western Pennsylvania and many drug-users become addicted unknowingly. Xylazine has circulated in Philadelphia since at least 2006, but it became more widely used after 2018. By now, over 90% of the city’s drug supply tests positive for xylazine. For people with active addiction there, becoming dependent on xylazine is all but inevitable.

But now, legalizing and distributing test strips can help users understand what they are about to put into their bodies, and avoid becoming dependent on xylazine to begin with. This could also make Pittsburgh an unattractive market for illicit xylazine, slowing its spread. Widespread tranq addiction is not inevitable in Pittsburgh.

Prevention has always been more effective than treatment. The question is: have we learned from our mistakes with fentanyl?